Moon Lake Immunotherapeutics MLTX
Institutional shares held
38.5 Million
4.13M
calls
1.54M
puts
Total value of holdings
$492M
$52.8M
calls
$19.6M
puts
Market Cap
$472M
36,925,600
Shares Out.
Institutional ownership
104.25%
# of Institutions
181
We take great care to ensure that the data presented and summarized in this overview for MoonLake Immunotherapeutics is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MLTX
View all-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.99MShares$25.5 Million2.28% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.7MShares$21.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY965KShares$12.3 Million0.05% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8894KShares$11.4 Million0.05% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD823KShares$10.5 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC636KShares$8.12 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL596KShares$7.61 Million0.01% of portfolio
Latest Institutional Activity in MLTX
Top Purchases
Top Sells
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Transactions at MLTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 08
2025
|
Matthias Bodenstedt Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,870
+1.7%
|
$97,830
$9.09 P/Share
|
|
Sep 30
2025
|
Bihua Chen |
SELL
Open market or private sale
|
Indirect |
5,827
-0.29%
|
$34,962
$6.96 P/Share
|
|
Sep 29
2025
|
Bihua Chen |
SELL
Open market or private sale
|
Indirect |
6,494,151
-25.83%
|
$45,459,057
$7.99 P/Share
|
|
Sep 02
2025
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,978
-58.05%
|
-
|
|
Sep 02
2025
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
48,978
+19.44%
|
-
|
|
Jul 03
2025
|
Catherine Moukheibir Director |
SELL
Open market or private sale
|
Direct |
23,500
-100.0%
|
$1,128,000
$48.79 P/Share
|
|
Jul 03
2025
|
Catherine Moukheibir Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,500
+50.0%
|
-
|
|
Feb 27
2025
|
Matthias Bodenstedt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,763
+13.44%
|
-
|
|
Feb 27
2025
|
Da Silva Jorge Santos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,763
+3.02%
|
-
|
|
Jan 20
2025
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
111,949
-57.02%
|
-
|
|
Jan 20
2025
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
111,949
+42.11%
|
-
|
|
Oct 04
2024
|
Bvf Partners L P Director |
SELL
Open market or private sale
|
Direct |
2,000,000
-9.26%
|
$100,000,000
$50.0 P/Share
|
|
Oct 04
2024
|
Simon Sturge Director |
SELL
Open market or private sale
|
Direct |
171,000
-49.86%
|
$9,063,000
$53.72 P/Share
|
|
Feb 29
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,740
-0.16%
|
$260,700
$55.89 P/Share
|
|
Feb 28
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
56,065
-1.84%
|
$3,083,575
$55.0 P/Share
|
|
Feb 28
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,090
-40.09%
|
$1,544,950
$55.0 P/Share
|
|
Feb 28
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
31,910
-1.08%
|
$1,755,050
$55.0 P/Share
|
|
Feb 27
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
62,810
-2.02%
|
$3,454,550
$55.0 P/Share
|
|
Feb 27
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
29,431
-29.58%
|
$1,618,705
$55.0 P/Share
|
|
Feb 27
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
29,491
-0.99%
|
$1,622,005
$55.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
387K
Shares
From
5
Insiders
| Exercise of conversion of derivative security | 23.5K shares |
|---|---|
| Grant, award, or other acquisition | 192K shares |
| Open market or private purchase | 10.9K shares |
| Conversion of derivative security | 161K shares |
Sell / Disposition
6.68M
Shares
From
3
Insiders
| Open market or private sale | 6.52M shares |
|---|---|
| Sale (or disposition) back to the issuer | 161K shares |